Randomized Trial of Atorvastatin for Lowering Cardiovascular Risk in Postpartum Women with Hypertensive Pregnancy Disorders

What this Trial Is About

Researchers are evaluating the use of atorvastatin to reduce cardiovascular risk in postpartum individuals who had hypertensive disorders during pregnancy, such as preeclampsia or gestational hypertension. This trial aims to see if taking atorvastatin after stopping breastfeeding can lower the risk of heart disease and improve related health markers. The study is a randomized, placebo-controlled trial designed to assess these effects over time. Participants will be randomly assigned to receive either atorvastatin 10 mg daily or a matching placebo, starting after they stop breastfeeding and continuing for 3 months. The study includes two groups one taking atorvastatin and the other taking placebo pills that look identical. After the treatment period, participants will be followed for up to one year to monitor lasting effects and health outcomes. During the study, participants will undergo regular assessments including cardiovascular risk scoring, blood tests for cholesterol and inflammatory markers, measurements of waist size and blood pressure, and evaluations for metabolic syndrome. Researchers will also track medication use, side effects, and healthcare visits. The main measurement is the 30-year Framingham Risk Score assessed after 3 months of treatment. Safety and effectiveness will be monitored throughout the study and after stopping the medication for several months.

AtorvaStatin Postpartum and Reduction of Cardiovascular risK